IGM Biosciences (NASDAQ:IGMS - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect IGM Biosciences to post earnings of ($0.74) per share and revenue of $0.39 million for the quarter.
IGM Biosciences Stock Performance
Shares of NASDAQ:IGMS traded up $0.02 on Friday, reaching $1.36. The company's stock had a trading volume of 141,685 shares, compared to its average volume of 593,125. IGM Biosciences has a 52-week low of $1.26 and a 52-week high of $22.50. The company has a market cap of $80.87 million, a P/E ratio of -0.37 and a beta of 0.03. The company has a 50-day simple moving average of $2.90 and a 200 day simple moving average of $9.07.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Wedbush restated a "neutral" rating and set a $3.00 price objective (down from $22.00) on shares of IGM Biosciences in a research note on Friday, January 10th. JPMorgan Chase & Co. raised IGM Biosciences from an "underweight" rating to a "neutral" rating in a research report on Monday, January 13th. Morgan Stanley lowered shares of IGM Biosciences from an "equal weight" rating to an "underweight" rating and reduced their price target for the stock from $12.00 to $2.00 in a research report on Friday, January 10th. Truist Financial decreased their price objective on IGM Biosciences from $12.00 to $2.00 and set a "hold" rating for the company in a report on Friday, January 10th. Finally, Stifel Nicolaus lowered shares of IGM Biosciences from a "buy" rating to a "hold" rating and dropped their price target for the company from $27.00 to $2.50 in a research report on Friday, January 10th. One analyst has rated the stock with a sell rating and nine have issued a hold rating to the company. According to data from MarketBeat, IGM Biosciences currently has a consensus rating of "Hold" and a consensus price target of $5.50.
Check Out Our Latest Analysis on IGMS
IGM Biosciences Company Profile
(
Get Free Report)
IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.
Further Reading
Before you consider IGM Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IGM Biosciences wasn't on the list.
While IGM Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
